Clinical trials
Carbapenem-Resistant Enterobacteriaceae clinical trials
Below are recruiting carbapenem-resistant enterobacteriaceae clinical trials, each written for real people, not researchers. We’re tracking 13 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06636890Enrolling by invitation
Testing a new method for detecting certain bacteria in lung infections
This study checks if a special test (Xpert Carba-R) can find a type of drug-resistant bacteria, called CRE, in fluid from the lungs and in rectal swabs. It might help doctors treat lower respiratory tract infections more effectively.
Nanjing, JiangsuAges 18–90 - NCT06001333Recruiting
Fecal transplant to clear superbugs from the gut
This study tests whether a fecal transplant (FMT) can remove certain antibiotic-resistant bacteria from your gut. It might help people who carry superbugs like CPE or VRE but aren't currently on antibiotics.
Chuncheon, Gangwon-doAges 20 years+ - NCT05871476Recruiting
Study to reduce resistant bacteria spread in young children
This study tests ways to reduce how a hard-to-treat bacterial germ spreads between hospitals, homes, communities, and animals. It focuses on children under 2 years old in the selected hospital area because they may be more likely to pick up and spread the bacteria.
Thái Bình, Thai BinhAges Up to 2 years - NCT04535661Recruiting
Study of who develops carbapenem-resistant infections in PICU children
This study looks at factors that make some hospitalized children in the pediatric intensive care unit (PICU) develop or carry germs called carbapenem-resistant Enterobacteriaceae. It aims to understand who is at higher risk and why, which may help prevent infections in the future.
Shanghai, Shanghai MunicipalityAges 4 weeks–18 years - NCT06258551Recruiting
Tracking hard-to-treat bacteria in ICU and transplant patients
This study will track how certain hard-to-treat bacteria spread and cause infections in people who are in the intensive care unit (ICU) or have had a stem cell transplant. The goal is to better understand and prevent these infections in vulnerable patients.
Houston, TexasAges 18 years+ - NCT07525089Enrolling by invitation
Treatment to Clear Resistant Bacteria from Your Gut
This study tests whether a new treatment called BM111 can safely clear two types of antibiotic-resistant bacteria (CRE and VRE) that live in your intestines without causing infection. You'd provide stool samples over several weeks to see if the bacteria levels drop.
SeoulAges 19–65 - NCT04014413Recruiting
Fecal transplant for gut and immune-related conditions
This trial studies whether fecal microbiota transplantation (FMT)—a medical procedure using stool from a screened donor to restore gut bacteria—can improve safety and outcomes for people with certain bowel, immune, and metabolic conditions. It may help if your symptoms are thought to be related to an unhealthy gut microbiome, though eligibility is broad and depends on specific safety factors.
Hong Kong, ShatinAges Any age - NCT04759001RecruitingPhase 1/Phase 2
Fecal treatment to clear gut bacteria resistant to antibiotics
This study tests a stool-based treatment (fecal microbiota treatment) to help remove “carbapenem-resistant” bacteria living in the gut. If you carry these bacteria without being sick, the goal is to reduce or stop that colonization.
RomeAges 18–90 - NCT05791396RecruitingPhase 1/Phase 2
Fecal microbiome therapy to clear hard-to-treat gut germs
This trial looks at a treatment made from stool donors (called fecal microbiome therapy) to help remove carbapenem-resistant gut bacteria in the body. It’s mainly for adults who recently tested positive for these bacteria on a rectal swab, and it checks whether the therapy can help eradicate the germs.
RomaAges 18–85 - NCT05979545RecruitingPhase 4
Early treatment with ceftazidime-avibactam for serious infections
This study tests an antibiotic called ceftazidime-avibactam for people with serious infections like bloodstream infections or pneumonia that started in the hospital or from a breathing machine. It aims to start treatment quickly after identifying the bacteria.
Kuala LumpurAges Any age - NCT06051513Recruiting
Testing colistimethate for CRE infection in hospitalized patients
This trial tests a medicine called colistimethate sodium for people in the hospital with a serious infection (pneumonia or bloodstream infection) caused by a resistant bacteria called CRE. The goal is to see if this antibiotic can effectively treat the infection.
Hefei, AnhuiAges 18–85 - NCT07086391Recruiting
Inhaled Polymyxin B for Resistant Pneumonia
This trial tests different ways of giving an inhaled antibiotic (polymyxin B) to people on a ventilator who have pneumonia caused by tough bacteria that don't respond to usual antibiotics. The goal is to find the best way to deliver the medicine to help clear the infection.
Fuzhou, FujianAges 18–90 - NCT07089186RecruitingPhase 3
Study of meropenem and pralurbactam for certain antibiotic-resistant infections
This trial tests a combination of two antibiotics (meropenem and pralurbactam) for treating serious infections caused by bacteria that are resistant to many other antibiotics. It may be an option for hospitalized patients with pneumonia, urinary tract infections, abdominal infections, or bloodstream infections.
ShanghaiAges 18–80
Hear when a new Carbapenem-Resistant Enterobacteriaceae trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for carbapenem-resistant enterobacteriaceae?
- Yes. Clin2 currently lists 13 recruiting carbapenem-resistant enterobacteriaceae studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a carbapenem-resistant enterobacteriaceae trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a carbapenem-resistant enterobacteriaceae trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.